Drug Therapy

The first subject has been dosed in a phase 1 clinical trial of an oral proteolysis-targeting chimera protein degrader to treat neurodegenerative diseases, according to the manufacturer.

Takeda has announced positive topline results from a phase 2b trial evaluating an oral orexin receptor 2 agonist to treat individuals with narcolepsy type 1.

The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.

Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s disease, deciding to discontinue development of Aduhelm and choosing to advance Leqembi.

Health Canada has approved Uplizna as a monotherapy for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.

IGC Pharma has announced that dosing has commenced at one of its sites participating in a phase 2b clinical trial of a combination therapy for agitation in dementia related to Alzheimer’s disease.

Combination behavioral and pharmaceutical therapy improved functionality and daytime symptoms of insomnia, while addition of a second treatment provided further benefits for the condition, according to research from JAMA Network Open.

A clinical-stage biopharmaceutical company has announced positive topline data from a study evaluating a novel, oral 5-HT2C receptor superagonist for seizures associated with developmental and epileptic encephalopathies.

Oragenics Inc. has announced the completion of its acquisition of assets related to Odyssey Health Inc., including its proprietary neurological drug therapies and technologies.

A biotechnology company announced the first patient was dosed in its phase 2a clinical trial of intranasal foralumab, a monoclonal antibody treatment for those with non-active secondary-progressive multiple sclerosis.